Neovacs SA (0W8U) AI Stock Analysis

0 Followers

Neovacs SA

(LSE:0W8U)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low Balance-Sheet LeverageVery low leverage limits the immediate burden of debt service and reduces refinancing exposure compared with a highly indebted biotechnology company. This gives Neovacs more flexibility to allocate capital toward research and development, although continued losses could still erode that advantage over time.

Negative Factors

Persistent UnprofitabilityPersistent losses indicate that the current business has not yet achieved sufficient commercial scale or cost coverage. Negative gross profit is especially concerning because it shows weakness before operating expenses, making sustained profitability dependent on materially better revenue, economics, or successful development outcomes.

Neovacs SA (0W8U) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: EUR 140.09K
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 0.0
Beta (1Y): 0.05
Revenue Growth: -9.52%
EPS Growth: 100.00%
Country: UK
Employees: 16
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Neovacs SA Business Overview & Revenue Model

Company Description

Based in Paris, France, Neovacs S.A. is a biotechnology firm established in 1993, dedicated to creating therapeutic vaccines for a range of conditions including autoimmune, inflammatory, allergic, and oncological diseases. The company leverages its p...

Neovacs SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0W8U against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:TNG	48Neutral	EUR 202.59M	-4.37	-29.36%	―	189.81%	38.50%
FR:VLA	47Neutral	EUR 509.31M	-2.92	-152.15%	―	-27.19%	-117.39%
FR:ABVX	44Neutral	EUR 7.29B	-17.52	-85.88%	―	―	―
FR:DBV	40Underperform	EUR 670.78M	-3.91	-121.83%	―	―	45.11%
FR:OSE	37Underperform	EUR 40.84M	-1.01	-96.73%	―	-96.25%	-197.89%

* Healthcare Sector Average

Performance Comparison

GB:0W8U and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0W8U	Neovacs SA	16000.00	0.00	0.00%
FR:ABVX	Abivax SA	82.50	-11.70	-12.42%
FR:DBV	Dbv Technologies SA (UK)	2.12	-0.20	-8.62%
FR:TNG	Transgene SA	0.73	-0.54	-42.52%
FR:VLA	Valneva (0OB3)	2.63	-1.23	-31.92%
FR:OSE	OSE Immunotherapeutics	1.70	-3.89	-69.55%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Neovacs SA AI Stock Analysis